Epithalon Dosage: Community Cycles & the Caveat
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Epithalon encyclopedia entry · See also: MOTS-c dosage · Regulatory tracker
Epithalon is investigational and not FDA approved, and its human evidence is limited and largely from a single Russian research group. There is no label or validated dose. The figures below are community reports, documented for education — not instructions for use.
The short version
Epithalon (often spelled Epitalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — that comes out of Russian gerontology research on pineal-gland extracts. It is one of the most popular "longevity" peptides online, largely on the strength of claims about telomerase activation and telomere maintenance. The crucial framing point is that the human evidence is thin and concentrated in one research lineage, so any dose is built on a small and not widely replicated foundation.
What community protocols report
Epithalon is unusual in that it is typically cycled in short courses rather than taken continuously.
| Parameter | Commonly reported |
|---|---|
| Amount | ~5–10 mg/day |
| Course length | ~10–20 days |
| Frequency of courses | 1–2× per year |
| Route | Subcutaneous |
The "short course, once or twice a year" pattern mirrors how the original Russian protocols were described, on a theory of periodic pineal "reset" rather than continuous dosing. Whether this maps to any human benefit is unproven — it is a convention inherited from the source research, not an independently validated schedule.
Where Epithalon stands legally
Epithalon was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 after nominations were withdrawn — which is not approval. It is scheduled for PCAC review on July 24, 2026. Until that concludes it remains outside the approved-medicine framework; see the Regulatory Status Tracker.
Reconstitution basics
Epithalon is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before a dose can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact syringe draw; it cannot, of course, verify the contents of an unregulated vial or substantiate the longevity claims.
Frequently asked questions
Does Epithalon really lengthen telomeres?
Telomerase-activation claims trace to the original research group's work; independent, large-scale human confirmation is lacking, so this should be treated as an unproven hypothesis rather than an established effect.
Why cycle it instead of taking it daily?
The short-course pattern comes from how the source protocols were structured; there is no robust human pharmacology that establishes an optimal schedule.
Is it approved now that it's off Category 2?
No. Removal from Category 2 is procedural; Epithalon awaits its July 2026 PCAC review and is not an approved medicine.
Sources
- Khavinson VK, et al. Effects of the pineal tetrapeptide (Epitalon) on aging markers — Russian gerontology research.
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026.
Medical disclaimer: Education only, not medical advice. Epithalon is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Consult a licensed clinician.